PRA Health Sciences Late Phase Services is participating in a global real world safety study program, mandated by various regulatory bodies, to confirm risk/benefit profile for a novel oral anticoagulant to assess the drug’s bleeding risk. Our ability to provide global operational oversight and efficiencies, ensure consistent communication with sites, and keep our patients engaged resulted in PRA becoming the client’s CRO of choice.
THE INSIGHT SERIES: Why do prescribers participate? - Part III
While Phase II-III studies include small datasets, comprising several hundred to several thousand patients, they provide the data necessary for drug…
21st Century Cures Act and Real-World Evidence
Careers at PRA
We know that people are our greatest strength, so we work hard to hire the very best. Then we nurture, challenge, and reward them so they want to…